[Federal Register Volume 67, Number 111 (Monday, June 10, 2002)]
[Notices]
[Pages 39730-39731]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-14439]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: ``Compound, Composition 
and Method For Treating Cancer'', U.S. Patent 6,235,761

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. Sec. 209(c)(1) 
and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license to practice the inventions embodied in United 
States Patent number 6,235,761, entitled, ``Compound, composition and 
method for treating cancer,'' which was issued on May 22, 2001 and 
claims priority to U.S. Patent Application S/N 60/019,086, entitled, 
``Compound, composition and method for treating cancer,'' which was 
filed on May 30, 1996, to Xanthus Life Sciences which is located in 
Cambridge, Massachusetts. The patent rights in these inventions have 
been assigned to the United States of America.
    The prospective exclusive license territory will be worldwide and 
the field of use may be limited to human therapeutics for the treatment 
of cancer.

DATES: Only written comments and/or license applications that are 
received by the National Institutes of Health on or before August 9, 
2002 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comments and 
other materials relating to the contemplated exclusive license should 
be directed to: Richard U. Rodriguez, Technology Licensing Specialist, 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD. 20852-3804. Telephone: 
(301) 496-7056, X287; Facsimile: (301) 402-0220; and E-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: The technology claimed in the issued patent 
relates to the 4-demethyl penclomedine molecule and all salts, both 
alone and in combination. The patent also claims use of the drug in 
treating cancer, especially solid tumors.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR Part 
404.7. The prospective exclusive license may be granted unless within 
sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establish that the grant of 
the license would not be consistent with the requirements of 35 U.S.C. 
209 and 37 CFR part 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.


[[Page 39731]]


    Dated: May 28, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 02-14439 Filed 6-7-02; 8:45 am]
BILLING CODE 4140-01-P